March 2026

Join WhatsApp Channel 

Regulatory Affairs Courses
Titan Laboratories hiring for Regulatory Affairs
5 March 2026

Titan Laboratories hiring for Regulatory Affairs

B.Pharm / M.Pharm with Communication skills, documentation expertise & problem-solving ability. Regulatory Affairs at Titan Labs
5 March 2026
Interviews for QC, AR&D, QA at Shodhana Laboratories
Candidates having Experience on Instrumentation, HPLC, UV, IR, Regulatory Knowledge, GMP Documentation.
5 March 2026
Applications invited in Production, Quality Control Department at Aspiro Pharma
Having Injectable Experience of Shop floor supervising activities like filtration, Filling, Sealing, Stoppering, Garment Washing, Vial Washing, Autoclave, Ophthalmic, Suspensions, Lyophilizes. Operations and Training and QMS.
5 March 2026
USV hiring Quality Assurance professionals
Validation professional with expertise in qualification / validation / re-qualification of instruments, equipment & utilities; hands-on validation through electronic systems; calibration & preventive maintenance.
5 March 2026
Work as First Line Leader at GSK
The First Line Leader is accountable for developing and enabling a frontline team of operators to consistently deliver exceptional safety, quality, service and cost‑effective products.
5 March 2026
CDSCO Issues Alert After Theft of Sanofi Lantus Insulin Pens During Transit

India’s drug regulator has issued a public advisory after a consignment of insulin pens manufactured by Sanofi India Limited was reported stolen during transportation, raising concerns about potential risks if the products enter the market through unauthorized channels.

5 March 2026
Moderna Settles Vaccine Patent Dispute with 950 Million USD Deal
Biotechnology company Moderna has announced a major settlement to resolve global patent litigation with Arbutus Biopharma Corporation and Genevant Sciences GmbH over technology used in its mRNA vaccines. The agreement settles all ongoing lawsuits worldwide related to the companies’ disputes.
5 March 2026
Sanofi’s rilzabrutinib earns orphan drug designation in Japan for IgG4-related disease
The Ministry of Health, Labour and Welfare (MHLW) in Japan has granted orphan drug designation to rilzabrutinib, a novel, oral, reversible covalent Bruton’s tyrosine kinase (BTK) inhibitor, for IgG4-related disease (IgG4-RD).
5 March 2026
US FDA Approves Glenmark’s Generic Fluticasone Propionate Inhaler for Asthma Treatment
Glenmark Specialty SA has received final approval from the U.S. Food and Drug Administration for Fluticasone Propionate Inhalation Aerosol USP
5 March 2026
CDSCO Announces Faster NOC Process for Drug Testing Before Approval
The regulator has announced that companies will now receive the No Objection Certificate, NOC more quickly, helping to streamline regulatory procedures and reduce approval timelines.